Alpha Cognition Inc. Stock Analysis ACOG.CN

Alpha Cognition Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Vancouver, British Columbia and currently employs 4 full-time employees. The company went IPO on 2018-09-19. Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The firm is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. The company is in preclinical development for the treatment of ALS.